[ad_1]
The two COVID-19 vaccine candidates being developed by Pfizer and Modena have a prevention rate of more than 90%.
This means that if you receive this vaccine, your risk of getting COVID-19 is reduced by more than 90%.
It is also very encouraging compared to vaccines for other diseases.
PD Bang Joo-hee complies.
[리포터]The prevention rate, which indicates the effectiveness of the vaccine, refers to the degree to which you have a lower risk of getting sick from the vaccine than if you were not.
The preventive effect of the COVID-19 candidate vaccine, which is jointly developed by Pfizer and Bioentech, is 90%, and the preventive effect of the Modena vaccine is 94.5%.
This means that if you receive any of the vaccines, your risk of getting COVID-19 will be reduced by more than 90%.
This exceeds the standards for approval of the use of vaccines proposed by the World Health Organization and the US Centers for Disease Control and Prevention.
This is also a very encouraging result considering that the influenza vaccine prevention rate is 20-60%.
Interim results of vaccine candidates that have a great effect on preventing COVID-19 infection are announced one after another, raising expectations that a breakthrough has been prepared for daily recovery.
Since Modena and Pfizer’s request for emergency use approval is likely to be made no later than early next month, a vaccine approved for emergency use by the US Food and Drug Administration may be available from this year.
Considering that the vaccine development period is typically 5-10 years, a new vaccine history will be released within a year of the Corona 19 outbreak.
Modena and Pfizer, as well as AstraZeneca, UK, are expected to publish the results of a phase 3 clinical trial in a few weeks.
In particular, the AstraZeneca vaccine is targeting 3 pounds per vaccine and around 4,300 won, attracting attention for its low price.
According to the New York Times, a total of 54 vaccines are in clinical trials, and a total of 12 vaccines, including Johnson & Johnson in the United States and Sinopharm in China, are known to be undergoing phase 3 trials, the final stage of the clinical trial.
This is Joo-hee Bang on Yonhap News TV.
Yonhap News TV article inquiries and reports: katok / line jebo23
<저작권자 (c) 연합 뉴스,
Unauthorized reproduction-redistribution prohibited>
2020/11/17 21:02 sent
